Ludwig Institute for Cancer Research Limited

Donata Rimoldi

Pierre G Coulie

Stefan Carrel

Daryl Reed

Victor Jongeneel

Jean-Charles Cerrottini

Thierry R Boon-Falleur

Etienne De Plaen

Francis Brasseur

Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.

Immunogenic compositions of tumor rejection antigen precursor MAGE-10 and an adjuvant

Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.

MAGE-10 encoding CDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof

A correlation between expression of tumor rejection antigen precursor MAGE-10 and cancer has been discovered. The invention is a method for determining presence of cancer in a sample by determining expression of MAGE-10. This determination can be made via, e.g., an immunoassay, an oligonucleotide hybridization assay, or via other standard methodologies.

Method for determining cancer by determining expression of MAGE-10

Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.1

MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof

Isolated tumor rejection antigen precursor MAGE-10 and compositions

Isolated CDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.1

Growing community of inventors

Epalinges, Switzerland

Donata Rimoldi